|1.||Wesierska-Gadek, Józefa: 17 articles (01/2011 - 09/2003)|
|2.||Meijer, Laurent: 13 articles (01/2015 - 06/2003)|
|3.||Maurer, Margarita: 10 articles (04/2011 - 10/2007)|
|4.||Hassan, Moustapha: 7 articles (06/2015 - 02/2004)|
|5.||Arisan, Elif Damla: 6 articles (06/2015 - 05/2012)|
|6.||Sallam, Hatem: 6 articles (06/2015 - 11/2007)|
|7.||Obakan, Pinar: 6 articles (06/2015 - 05/2012)|
|8.||Galons, Hervé: 6 articles (01/2015 - 09/2005)|
|9.||Komina, Oxana: 6 articles (04/2011 - 12/2008)|
|10.||Lane, David P: 6 articles (01/2009 - 12/2002)|
06/01/2015 - "Roscovitine is widely used as a biological tool in cell cycle, cancer, apoptosis and neurobiology studies. "
12/01/2013 - "Although a number of studies have demonstrated the potential apoptotic role of roscovitine, there is limited data about the therapeutic efficiency of purvalanol on cancer cells. "
09/01/2011 - "This study provides first information on how to modify roscovitine to develop Cdk inhibitors with increased antiangiogenic activity and suggests the application of existing and the development of new Cdk inhibitors to inhibit both, cancer cell proliferation and angiogenesis."
01/01/2011 - "In this study, we examined whether the CDK inhibitor roscovitine confers a tumor suppressive effect on therapy-resistant breast epithelial cells. "
04/01/2009 - "Our model of open channel block by roscovitine may offer an explanation of the lack of arrhythmias in clinical trials using roscovitine, which suggests the utility of a dual CDK/HERG channel block as an adjuvant cancer therapy."
05/01/2011 - "Seliciclib is effective in both prevention and treatment of established crescentic glomerulonephritis in Wistar Kyoto rats, in association with a reduction in the number of glomerular macrophages. "
11/15/1997 - "We conclude that reducing the activity of CDK2 with Roscovitine in experimental glomerulonephritis decreases cell proliferation and matrix production, resulting in improved renal function, and may be a useful therapeutic intervention in disease characterized by proliferation."
05/01/2011 - "In experiment 2, treatment was started on day 4 of NTN and continued to day 14 in order to examine the effect of seliciclib in established glomerulonephritis. "
01/01/2012 - "In an in vivo glomerulonephritis model, roscovitine treatment decreased mesangial cell proliferation and matrix proteins . "
03/01/2005 - "To determine if decreasing podocyte proliferation improves renal function, CDK2 activity was reduced with the purine analogue roscovitine in mice with antibody-induced experimental glomerulonephritis. "
03/01/2005 - "Inhibiting CDK2 activity resulted in a marked decrease in glomerular DNA synthesis [5-bromo-2'-deoxyridine (BrdU) staining] in Roscovitine-treated animals at day 5 of nephritis (P < 0.05 versus control). "
05/01/2007 - "To examine whether the cyclin-dependent kinase (CDK) inhibitor seliciclib ameliorates autoimmune nephritis in (NZB x NZW)F(1) mice. "
02/01/2005 - "The aim of the study was to evaluate the effects of Mycophenolate mofetil (MMF), and roscovitine (R), on the cell cycle regulatory system when administered in the florid phase of the experimental model of mesangial proliferative nephritis induced by the anti Thy-1 antigen monoclonal antibody. "
04/01/2005 - "R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury."
02/01/2005 - "Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis."
|4.||Breast Neoplasms (Breast Cancer)
04/01/2011 - "Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells."
09/10/2003 - "The aim of our study was to explore the antiproliferative and pro-apoptotic action of roscovitine (ROSC) on human breast cancer MCF-7 cells. "
08/01/2009 - "Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells."
06/01/2008 - "In summary, our results reveal a pleitropic mechanism for the pro-apoptotic influence of roscovitine, highlighting its potential as an antitumor agent in breast cancer in combination with TRAIL."
06/01/2008 - "In addition, we demonstrate that roscovitine strongly suppressed Mcl-1 expression and up-regulated E2F1 protein levels in breast tumor cells. "
06/15/2005 - "This study provides the scientific rationale for the clinical development of seliciclib for the treatment of multiple myeloma."
06/15/2005 - "This study investigated the mechanism of cell death in multiple myeloma cells treated with seliciclib. "
01/01/2011 - "Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells."
08/01/2005 - "Here we studied the in vitro cytotoxic activity of seliciclib against multiple myeloma (MM) cells. "
01/01/2011 - "In the present study we addressed the possibility that pharmacological CDK inhibitors like Roscovitine (ROSC) may be effective against human multiple myeloma cells that have acquired resistance to doxorubicin (DOX). "
|3.||Cyclin-Dependent Kinases (cdk Proteins)
|6.||DNA (Deoxyribonucleic Acid)
|8.||2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
|10.||Mitogen-Activated Protein Kinase 3
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)